AnalystBook Research · Company Intelligence

ONTO INNOVATION INC.

ONTONYSE

Built from ONTO INNOVATION INC.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Onto Innovation grew revenue, remained profitable, generated positive free cash flow at a 13.2% operating margin. Inventory grew faster than revenue, while margins and free cash flow remained strong.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue grew 1.8%OK
  • ProfitabilityNet income declined 32.2% to $136.759M from $201.67MWatch
  • Cash flowFree cash flow grew 40.2% to $299.802M from $213.773MOK
  • MarginsOperating margin contracted 573 bps to 13.22%Watch
  • AccountingInventory grew faster than revenue, while margins and free cash flow remained strongNote
  • Insiders0 purchases and 0 salesNote

Business

Onto Innovation makes semiconductor inspection, metrology and process-control equipment.

Leadership changes

From ONTO INNOVATION INC.'s own filings, the day they're filed.

  • Brian Roberts · Chief Financial Officer · appointmenteff. 2025-06-16
  • Purdue University · director · appointment
  • MidAmerica Nazarene University · directors · appointment

Latest filings

  • 8-K · Company announcement2026-08-10
  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-08-06
  • 8-K · Company announcement2026-05-21
  • 8-K · Company announcement2026-05-20
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about ONTO INNOVATION INC., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.